Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

15.1%

229 terminated/withdrawn out of 1512 trials

Success Rate

80.2%

-6.3% vs industry average

Late-Stage Pipeline

9%

133 trials in Phase 3/4

Results Transparency

41%

381 of 929 completed trials have results

Key Signals

199 recruiting381 with results114 terminated115 withdrawn

Enrollment Performance

Analytics

N/A
680(60.4%)
Phase 2
156(13.9%)
Phase 1
131(11.6%)
Phase 4
106(9.4%)
Phase 3
27(2.4%)
Early Phase 1
25(2.2%)
1125Total
N/A(680)
Phase 2(156)
Phase 1(131)
Phase 4(106)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (1512)

Showing 20 of 1512 trials
NCT07639515Not ApplicableNot Yet Recruiting

Randomized In-Vivo Comparison of 3D-Printed and Thermoformed Clear Aligners: A Multi-Subject, Time-Dependent Analysis of Adaptation and Trueness

Role: lead

NCT05415761Not ApplicableRecruiting

Comparative Effectiveness of Mobile Health Smoking Cessation Approaches Among Underserved Patients in Primary Care

Role: lead

NCT05628389Not ApplicableRecruiting

Phone Enabled Implementation of Cessation Support

Role: lead

NCT07606001Not ApplicableRecruiting

Yellow Potatoes and Carotenoids

Role: lead

NCT06934395Not ApplicableActive Not Recruiting

SHARE Program: SUSTAIN

Role: collaborator

NCT07643519Phase 2Not Yet Recruiting

Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma

Role: lead

NCT05047172Phase 3Active Not Recruiting

Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis

Role: lead

NCT06448091Not ApplicableRecruiting

Trial of Precision Medicine in Emergency Departments

Role: lead

NCT05618080Active Not Recruiting

LGMD R1 Natural History Study

Role: collaborator

NCT06316934Phase 2Terminated

Lavender Aromatherapy to Decrease Anxiety/Pain Perception During Office Hysteroscopy

Role: lead

NCT03981575Recruiting

Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)

Role: collaborator

NCT06514898Phase 1Recruiting

Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma

Role: lead

NCT07634640Early Phase 1Recruiting

Hearts on Fire: Targeting Inflammation in Heart Failure With Preserved Ejection Fraction

Role: lead

NCT07636447Not ApplicableNot Yet Recruiting

Alcohol Sensitivity Among Older Adults Who Consume Alcohol

Role: lead

NCT06868238Phase 2Recruiting

Evaluation of Novel Iron-based Lymphatic Mapping Agent, Magtrace, for Delayed Sentinel Lymph Node Biopsy (SLNB) in Ductal Carcinoma In-Situ (DCIS)

Role: lead

NCT06979726Phase 4Recruiting

Gator SCALES-WHF: SubCutaneous Administration of Lasix to Eliminate Symptoms of Worsening Heart Failure

Role: lead

NCT07597070Phase 2Not Yet Recruiting

Universal Immunization to Fortify Immunotherapy Efficacy and Response

Role: lead

NCT06722807Not ApplicableRecruiting

ClAmpless, Sutureless PartIAl Nephrectomy for Renal Masses

Role: lead

NCT07633561Not ApplicableNot Yet Recruiting

Feasibility and Clinical Utility of Ambulatory Ultraslow Deflation Sphygmomanometers in LVAD Recipients - easiSLOW-LVAD Pilot

Role: lead

NCT06402357Phase 2Recruiting

High Intensity Focused Ultrasound in Prostate Cancer

Role: lead